Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MALVERN, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing breakthrough gene therapies and vaccines, announced that it has signed a non-binding letter of intent (LOI) with Liminal BioSciences, Inc. a Canadian public company with shares listed on NASDAQ   for the acquisition of their manufacturing site in Belleville, Ontario, for an undisclosed amount.

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

I would take a closer look at the rest of its pipeline before buying, but consider OCGN stock one to keep on your watchlist. The post Despite Big Disappointment, There's Still Potential With Ocugen Stock appeared first on InvestorPlace.

Despite Big Disappointment, There's Still Potential With Ocugen Stock

MALVERN, Pa., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the appointment of Nirdosh Jagota, Ph.D.,  as Senior Vice President (SVP), Regulatory Affairs, compliance and safety.

Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety

MALVERN, Pa., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 787,268 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 217,681 shares of common stock to three newly hired team members. The stock options and RSUs were granted on January 10, 2022, and January 17, 2022, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). 687,872 of the stock options and 190,198 of the RSUs were issued on January 10, 2022, to a new member of the management team, whose appointment will be announced at a later date.

Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AeroCentury

Vinco Ventures

Gevo

Insignia Systems

MicroVision

Phunware Inc

Watch out with these seven penny stocks, a mix of plays that are still flying high, and a few that have already seen their bubble deflate. The post 7 Penny Stock Bubbles That Are Bound to Burst appeared first on InvestorPlace.

7 Penny Stock Bubbles That Are Bound to Burst

BioNTech SE

Moderna

Novavax

Several factors are dragging down these vaccine stocks.

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week

FuelCell Energy

Can these high-volume penny stocks continue to push up? The post 3 Penny Stocks That Investors Are Watching Right Now And Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Investors Are Watching Right Now And Why

Are these penny stocks worth buying right now? The post Check These 3 Penny Stocks Out For Next Week's Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Next Week's Watchlist

While it's an extremely speculative idea, OCGN stock may receive a lifeline from the faith-based community due to a recent tragedy. The post Can the Faithful Provide a Lifeline to Ocugen?

Can the Faithful Provide a Lifeline to Ocugen?

Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.

Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 11% during intraday trading before closing up 0.24% today. This is why it happened.

Ocugen (OCGN) Stock: Why The Price Went Up Today

The coronavirus vaccine that it has licensed does very well against variants like omicron, but it's still a laggard.

Why Ocugen Stock Couldn't Outrun the Market Today

Shares of OCGN stock are in the green after Covaxin demonstrated strong protection against the omicron and delta variants. The post OCGN Stock Alert: Why Is Ocugen Soaring 10% Today?

OCGN Stock Alert: Why Is Ocugen Soaring 10% Today?

Ocugen Inc (NASDAQ: OCGN) and its partner, Bharat Biotech, announced results from a COVID-19 vaccine booster study conducted at Emory University. The data demonstrated sera from subjects who received a booster dose of candidate vaccine Covaxin six months after getting a primary two-dose series of Covaxin neutralized the SARS-CoV-2 Omicron and Delta variants.

Ocugen-Bharat Biotech Partnered COVID-19 Booster Covaxin Neutralizes Omicron, Delta Variants

Bluejay Diagnostics

Immix Biopharma

Here are three penny stocks to add to your watchlist right now The post Check These 3 Penny Stocks Out For Your Morning Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Morning Watchlist

The shares of biotech name Ocugen Inc (NASDAQ:OCGN) are popping in pre-market trading, last seen up 11.1% at $4.62, following news that the company's Covid-19 booster vaccine --Covaxin -- showed efficacy in neutralizing both the omicron and delta variants.

Ocugen Stock Looks Ready to Rebound on Upbeat Booster News

MALVERN, Pa., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, and its partner, Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine COVAXIN™ (BBV152) six months after getting a primary two-dose series of COVAXIN™ (BBV152) neutralized the SARS-CoV-2 Omicron and Delta variants. Earlier studies demonstrated the neutralizing potential of COVAXIN™ (BBV152) against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa.

COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

Inovio Pharmaceuticals

Both companies could become notable latecomers in the coronavirus vaccine market.

Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals

Adamis Pharmaceuticals

Bone Biologics Corp

These penny stocks climbed today, here's why The post 3 Penny Stocks to Watch With the Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch With the Stock Market Down Today

Ocugen's stock is up more than 5% after the latest clinical trial results showed its Covid-19 vaccine booster shot had positive results. The post OCGN Stock Alert: Why Is Ocugen Gaining Today?

OCGN Stock Alert: Why Is Ocugen Gaining Today?

Shares of Ocugen Inc. OCGN, -1.69% were up 8.1% in premarket trading on Monday, two days after a preprint came out Friday outlining Phase 2 clinical trial results for a COVID-19 booster dose being developed by Bharat Biotech, a privately held biotech based in Hyderabad. A preprint is a type of preliminary medical research that has not been peer-reviewed and is a common way to put out scientific information during the pandemic.

Ocugen's stock gains 8% on promising COVID-19 booster data from partner Bharat Biotech

Ocugen Inc (NASDAQ: OCGN) announced that a booster shot of the COVID-19 vaccine candidate generated over a 10-fold increase in antibody levels across a range of coronavirus variants. Disclosing the Phase 2 data posted by its partner Bharat Biotech for Covaxin, Ocugen said that the studies on its effectiveness against the Omicron variant are ongoing.

Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose

MALVERN, Pa., Jan. 08, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that its partner, Bharat Biotech, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™ (BBV152), in participants ages 12-64, receiving a booster dose six months following a second dose on the pre-print server, medRxiv. The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy.

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Could Ocugen Become the Next Moderna?

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc . (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in H.C. Wainwright's Bioconnect Conference taking place next week on January 10-13, 2022.

News for Ocugen, Inc. Stock (OCGN)